Oxbryta (Voxelotor) Leads
Connect with sickle cell disease patients and their families who suffered serious adverse events, including vaso-occlusive crisis, stroke, or death, from the recalled drug Oxbryta (voxelotor).
Oxbryta Sickle Cell Drug Litigation
Oxbryta (voxelotor), manufactured by Pfizer (formerly Global Blood Therapeutics), was approved to treat sickle cell disease in patients aged four and older. The FDA requested Pfizer voluntarily withdraw the drug from the market after post-marketing data revealed an imbalance of deaths and vaso-occlusive crises in patients taking Oxbryta compared to placebo. Lawsuits allege the manufacturer downplayed safety signals and continued marketing the drug despite evidence of serious harm.
Associated Conditions
- Vaso-occlusive crisis
- Death
- Stroke
- Acute chest syndrome
- Organ damage
- Worsening sickle cell complications
- Hospitalization for adverse drug events
Claimant Eligibility
- Prescribed and took Oxbryta (voxelotor) for sickle cell disease
- Experienced vaso-occlusive crisis, stroke, or other serious adverse event
- Hospitalized or required emergency treatment while on Oxbryta
- Family member of a patient who died while taking Oxbryta
- Medical records confirming Oxbryta prescription and adverse events
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Running a Oxbryta (Voxelotor) mass tort marketing campaign
Common questions from law firms about Oxbryta (Voxelotor) lead generation and campaign management.
- What does a Oxbryta (Voxelotor) mass tort marketing campaign include?
- A Oxbryta (Voxelotor) mass tort marketing campaign from Mass Tort Marketing Agency covers channel strategy across Meta, Google/PPC, OTT, and mass tort SEO; compliant ad creative; TCPA-verified intake; claimant qualification against your Oxbryta (Voxelotor) case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- Are Oxbryta (Voxelotor) leads exclusive to my firm?
- Yes. Every Oxbryta (Voxelotor) lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Oxbryta (Voxelotor) claimants qualified before delivery?
- Each Oxbryta (Voxelotor) claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a TrustedForm or Jornaya consent token captured under the FCC one-to-one consent standard before the lead reaches your intake team.
- How is a Oxbryta (Voxelotor) campaign priced?
- Campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. You can scale volume up or down by tort as your docket capacity changes.
See how every lead is qualified on our mass tort leads page, or compare providers in our top mass tort marketing firms guide.